OR (95% CI) | B(SE) | P-value | McKelvey & Zavoina Pseudo R2 | |
---|---|---|---|---|
Quality of registration | ||||
Episodes with a meaningful diagnosis | 0.047 | |||
0–70% of episodes | ref | |||
More than 70% of episodes | 1.59 (1.26–2.01) | 0.46 (0.12) | < 0.001 | |
Contacts linked to an episode | 0.047 | |||
0–80% of contacts | ref | |||
More than 80% of contacts | 0.61 (0.47–0.80) | -0.49 (0.14) | < 0.001 | |
Collaboration | ||||
Participation in pharmacotherapy audit meetings | 0.043 | |||
Yes | ref | |||
No | 1.20 (0.68–2.10) | 0.18 (0.29) | 0.53 | |
Number of procedures with pharmacist | 0.043 | |||
0–5 topics | ref | |||
6–8 topics | 1.05 (0.77–1.41) | 0.046 (0.15)0.13 (0.16) | 0.77 | |
9–10 topics | 1.13 (0.83–1.55) | 0.43 | ||
Agreement with pharmacist on coprescribing laxative | 0.045 | |||
No | ref | |||
Yes | 1.32 (0.92–1.89) | 0.28 (0.18) | 0.13 | |
Use of an electronic clinical decision support system (%) | ||||
Always | ref | 0.044 | ||
In half or more than half of all prescriptions | 0.98 (0.70–1.38) | -0.019(0.17)-0.11 (0.16)-0.23 | 0.91 | |
In less than half of all prescriptions | 0.89 (0.65–1.22) | (0.16) | 0.49 | |
Never to hardly ever | 0.80 (0.58–1.09) | 0.16 | ||
Agree with guideline recommendations | ||||
Yes | ref | 0.044 | ||
No | 1.56 (0.93–2.62) | 0.44 (0.26) | 0.091 |